Full-Time

Director of Product and Commercial Strategy

Prolaio

Prolaio

51-200 employees

Real-time cardiovascular care analytics platform

Compensation Overview

$197k/yr

+ Bonus + Equity

Chicago, IL, USA

In Person

Category
Business & Strategy (2)
,
Required Skills
Sales
Product Management
Marketing
Financial Modeling
Requirements
  • 8+ years in Product Management, Product Strategy, or Corporate Strategy roles
  • Demonstrated experience in upstream product work: market sizing, competitive analysis, pricing strategy, and persona development
  • Domain experience in Digital Health, MedTech, or Life Sciences
  • Strong analytical skills with comfort in financial modeling (unit economics, margin analysis, TAM/SAM/SOM)
  • Excellent communication skills with ability to translate complex technical capabilities into business value
Responsibilities
  • Own the company’s market and competitive intelligence function. Go beyond surface-level analysis to deconstruct competitor capabilities (sensor fidelity, algorithm claims, clinical evidence, pricing structures). Maintain a live Threat Matrix covering direct competitors and asymmetric.
  • Conduct ongoing TAM/SAM/SOM analysis and identify emerging market segments, adjacencies, and white space opportunities.
  • Monitor regulatory, reimbursement, and industry trends that impact product-market fit.
  • Design the SKU architecture for our hardware-enabled SaaS model. Develop tiered packaging (Good/Better/Best) that supports upsell motion and aligns with customer value perception.
  • Drive the transition from cost-plus pricing to value-based pricing models. Partner with Finance to model unit economics and margin implications of packaging decisions.
  • Validate willingness-to-pay for new features and capabilities before development investment, partnering with the Chief Commercial Officer on pricing research.
  • Develop deep, data-driven archetypes for our two distinct customer segments:
  • Conduct ongoing customer research (interviews, surveys, usage analysis) to validate and evolve personas over time.
  • Translate personas into clear problem statements and Jobs-to-be-Done frameworks that inform product priorities.
  • Define value propositions for each feature set. Translate technical specifications into commercial benefits to arm Marketing and Sales.
  • Partner with the Director of Product Management to influence roadmap priorities based on market insights, competitive dynamics, and commercial opportunity. Provide the strategic rationale for sequencing decisions.
  • Serve as the voice of the market in product planning discussions, ensuring the roadmap balances near-term revenue needs with long-term strategic positioning.
  • Partner with the Chief Commercial Officer (CCO) to ensure product strategy aligns with go-to-market motion and sales capacity.
  • Work with the Chief Medical Officer (CMO) to validate that personas reflect clinical reality and that product solves genuine clinical problems.
  • Collaborate with Marketing on positioning, messaging, and competitive differentiation.
  • Support Business Development with market analysis for partnership and M&A evaluation.
Desired Qualifications
  • Experience with hardware + software product models
  • Familiarity with clinical trial operations and pharmaceutical commercialization

Prolaio provides a cardiovascular-focused health tech platform that helps healthcare providers improve patient outcomes through real-time data analytics and continuous monitoring. It collects data from electronic health records, patient surveys, and wearable sensors to build predictive models that warn care teams about potential health issues before they become critical. Healthcare providers access the platform via a subscription, giving them real-time analytics, alerts, and evidence-based care planning tools to monitor patients and optimize treatments. The company differentiates itself by concentrating on cardiovascular care and enabling continuous learning, patient engagement, and collaboration with pharmaceutical companies and research institutions to support new therapies. The overall goal is to reduce hospital admissions and readmissions while delivering timely, data-driven care that keeps patients healthier.

Company Size

51-200

Company Stage

Early VC

Total Funding

$25.5M

Headquarters

Scottsdale, Arizona

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Kardigan acquisition integrates Prolaio's data platform with cardiac intelligence.
  • Supports all-remote heart studies generating high-density CV insights.
  • Curates largest CV dataset to prevent avoidable heart events.

What critics are saying

  • Data incompatibility with Kardigan's R&D systems erodes value in 12-18 months.
  • FDA scrutiny halts platform use in trials and triggers fines in 6-12 months.
  • Key personnel loss stalls analytics updates in 3-6 months.

What makes Prolaio unique

  • Prolaio's FDA-cleared software integrates real-world CV data with proprietary algorithms.
  • Comprehensive patient kit includes wrist monitor, smart cuff, scale, and ECG patches.
  • Tech-enabled trial enrichment optimizes CV study design and boosts statistical power.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Prolaio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Stock Options

Company Equity

Retirement Plan: 401(k) plan

Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

7%

2 year growth

12%
Business Wire
Mar 28th, 2025
Kardigan Acquires Prolaio to Create a Pioneering Heart Health Company with One-of-a-Kind Integrated Cardiovascular Data and Therapeutics Platform

Kardigan, a heart health company modernizing cardiovascular (CV) drug development, announced today that it has acquired Prolaio, a clinical intelligence comp...

Securities and Exchange Commission
Sep 13th, 2023
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.